260 related articles for article (PubMed ID: 21226944)
1. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
3. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
4. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
Dineen SP; Roland CL; Greer R; Carbon JG; Toombs JE; Gupta P; Bardeesy N; Sun H; Williams N; Minna JD; Brekken RA
Cancer Res; 2010 Apr; 70(7):2852-61. PubMed ID: 20332237
[TBL] [Abstract][Full Text] [Related]
5. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Greer RM; Peyton M; Larsen JE; Girard L; Xie Y; Gazdar AF; Harran P; Wang L; Brekken RA; Wang X; Minna JD
Cancer Res; 2011 Dec; 71(24):7640-8. PubMed ID: 22049529
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
[TBL] [Abstract][Full Text] [Related]
8. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
9. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
[TBL] [Abstract][Full Text] [Related]
10. Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.
Sun Q; Zheng X; Zhang L; Yu J
Clin Cancer Res; 2011 Apr; 17(8):2361-72. PubMed ID: 21242120
[TBL] [Abstract][Full Text] [Related]
11. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
12. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
[TBL] [Abstract][Full Text] [Related]
16. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
[TBL] [Abstract][Full Text] [Related]
17. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
[TBL] [Abstract][Full Text] [Related]
18. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Zhou B; Zhang J; Chen G; You L; Zhang TP; Zhao YP
Cancer Lett; 2013 Feb; 329(1):118-24. PubMed ID: 23142291
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells.
Liu P; Feng J; Sun M; Yuan W; Xiao R; Xiong J; Huang X; Xiong M; Chen W; Yu X; Sun Q; Zhao X; Zhang Q; Shao L
Int J Oncol; 2017 Dec; 51(6):1878-1886. PubMed ID: 29039524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]